Connie Peet
University College London Hospitals NHS Foundation Trust
Internal medicineRadiologyOncologyStage (cooking)Medical physicsPositron emission tomographyNeuroblastomaRadiation protectionGamma cameraConventional treatmentRegimenMetastatic thyroid cancerTargeted radionuclide therapyRadioactive iodine177 LutetiumAbsorbed Radiation DoseToxicityMode of deliveryRadionuclide therapyHigh risk neuroblastomaRefractoryRadiation therapyClinical trialMedicineDosimetry
3Publications
1H-index
8Citations
Publications 3
Newest
#1Matthew D. Aldridge (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 5
#2Connie Peet (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 1
Last. Mark N. Gaze (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 28
view all 7 authors...
The common contemporary indications for paediatric molecular radiotherapy (pMRT) are differentiated thyroid cancer and neuroblastoma. It may also have value in neuroendocrine cancers, and it is being investigated in clinical trials for other diseases. pMRT is the prototypical biomarker-driven, precision therapy, with a unique mode of delivery and mechanism of action. It is safe and well tolerated, compared with other treatments. However, its full potential has not yet been achieved, and its wide...
1 CitationsSource
#2April-Louise Smith (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 1
Last. Mark N. GazeH-Index: 28
view all 9 authors...
Molecular radiotherapy, or targeted radionuclide therapy, uses systemically administered drugs bearing a suitable radioactive isotope, typically a beta emitter. These are delivered via metabolic or other physiological pathways to cancer cells in greater concentrations than to normal tissues. The absorbed radiation dose in tumour deposits causes chromosomal damage and cell death. A partner radiopharmaceutical, most commonly the same vector labelled with a different radioactive atom, with emission...
Source
#1Jennifer E. Gains (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 9
#2Veronica Moroz (University of Birmingham)H-Index: 9
Last. Mark N. Gaze (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 28
view all 9 authors...
PURPOSE: The objective of this phase IIa, open-label, single-centre, single-arm, two-stage clinical trial was to evaluate the safety and activity of 177-lutetium DOTATATE (LuDO) molecular radiotherapy in neuroblastoma. METHODS: Children with relapsed or refractory metastatic high-risk neuroblastoma were treated with up to four courses of LuDO. The administered activity was 75 to 100 MBq kg(-1) per course, spaced at 8- to 12-week intervals. Outcomes were assessed by the International Neuroblastom...
6 CitationsSource